2-Deoxy-2,2-difluoro-D-erythro-pentofuranose-3,5-dibenzoate-1-methanesulfonate Chemical Properties

Melting point:

66-74°C

Boiling point:

588.4±50.0 °C(Predicted)

Density 

1.46±0.1 g/cm3(Predicted)

storage temp. 

2-8°C

solubility 

Chloroform, Methanol

form 

Solid

color 

Off-White to Pale Yellow

optical activity

96.07°(C=0.01g/ml CHCL3)

InChI

InChI=1S/C20H18F2O8S/c1-31(25,26)30-19-20(21,22)16(29-18(24)14-10-6-3-7-11-14)15(28-19)12-27-17(23)13-8-4-2-5-9-13/h2-11,15-16,19H,12H2,1H3/t15-,16-,19?/m1/s1

InChIKey

LIAQHZDWFACWFK-QNRNLVPOSA-N

SMILES

C1(OS(C)(=O)=O)O[C@H](COC(=O)C2=CC=CC=C2)[C@@H](OC(=O)C2=CC=CC=C2)C1(F)F

CAS DataBase Reference

122111-11-9(CAS DataBase Reference)

2-Deoxy-2,2-difluoro-D-erythro-pentofuranose-3,5-dibenzoate-1-methanesulfonate Usage And Synthesis

Chemical Properties

Brown Liquid

Uses

Gemcitabine intermediate.

Synthesis

((2R,3R)-3-(Benzoyloxy)-4,4-difluoro-5-hydroxytetrahydrofuran-2-yl)methyl benzoate (4.14 g, 10.9 mmol) was dissolved in anhydrous dichloromethane (52 mL), anhydrous triethylamine (2.4 mL) was added, and the solution was cooled to 0 °C. Methylsulfonyl chloride (1.23 mL, 15.8 mmol) was added slowly and dropwise with stirring. The reaction mixture was stirred at room temperature for 18 hours. After completion of the reaction, the mixture was diluted with dichloromethane (140 mL) and washed with saturated sodium bicarbonate solution (56 mL). The organic phase was dried with anhydrous sodium sulfate and concentrated under reduced pressure to give an oily product as a mixture of isomers (5.03 g, quantitative yield). 19F NMR (CDCl3, 471 MHz): δ -107.70, -108.22, -120.65, -121.17, -122.21, -122.73, -123.76, -124.45. 1H NMR (CDCl3, 500 MHz) of the major isomer (60%): δ 8.13-8.04 (m, 4H, Bz), 7.65-7.54 (m, 2H, Bz), 7.50-7.41 (m, 4H, Bz), 6.17 (d, J = 5.6 Hz, 1H, H-1), 5.62 (dd, J1 = 4.2 Hz, J2 = 16.4 Hz), 5.62 (dd, J1 = 16.4 Hz, J2 = 16.4 Hz, J2 = 16.4 Hz). J2 = 16.4 Hz, 1H, H-3), 4.91 (q, J = 3.9 Hz, 1H, H-4), 4.81-4.61 (m, 2H, H-5), 3.17 (s, 3H, CH3). 1H NMR (CDCl3, 500 MHz) of the secondary isomer (40%): δ 8.13-8.04 (m, 4H, Bz), 7.65-7.54 (m, 2H, Bz), 7.50-7.41 (m, 4H, Bz), 6.09 (d, J = 6.4 Hz, 1H, H-1), 5.98 (dt, J1 = 7.3 Hz, J2 = 15.0 Hz, 1H, H-3), 4.81-4.61 (m, 3H, H-4, H-5), 3.03 (s, 3H, CH3). 13C NMR (CDCl3, 126 MHz): δ 40.09, 40.20 (CH3), 62.52, 63.08 (C-5), 69.61 (dd, J1C-F = 15.7 Hz, J2C-F = 26.0 Hz, C-3), 71.04 (dd, J1C-F = 17.4 Hz, J2C-F = 36.4 Hz C-3), 79.68, 79.75, 82.59 (C-4), 98.81 (dd, J1C-F = 25.0 Hz, J2C-F = 41.8 Hz, C-1), 99.52 (dd, J1C-F = 24.5 Hz, J2C-F = 46.3 Hz, C-1), 120.61 (dd, J1C-F = 253.5 Hz, J2C-F = 269.8 Hz, C-2), 120.91 (dd, J1C-F = 249.3 Hz, J2C-F = 276.3 Hz, C-2), 128.42, 128.58, 128.63, 128.70, 128.76, 128.79 (Ph), 129.18, 129.25 ('ipso ' Ph), 129.76, 130.07, 130.14, 133.51, 133.63, 134.19, 134.26 (Ph), 164.89, 165.03, 165.81, 165.90 (CO).

References

[1] Synthesis, 1992, # 6, p. 565 - 570
[2] Bioorganic and Medicinal Chemistry, 2011, vol. 19, # 14, p. 4338 - 4345
[3] Patent: WO2009/61781, 2009, A1. Location in patent: Page/Page column 102-103
[4] Biochemistry, 2010, vol. 49, # 7, p. 1404 - 1417
[5] Patent: WO2005/95430, 2005, A1. Location in patent: Page/Page column 18

2-Deoxy-2,2-difluoro-D-erythro-pentofuranose-3,5-dibenzoate-1-methanesulfonate(122111-11-9)Related Product Information

• Pazufloxacin mesilate
• Imatinib
• Gabexate mesylate
• Levofloxacin Methylate
• Methyl methanesulfonate
• Trifluoromethanesulfonic acid
• N-Carboxybenzyl GeMcitabine
• Ethyl (3R,S)-2,2-difluoro-3-hydroxy-3-(2,2-dimethyldioxolan-4-yl)propionate
• 2-Deoxy-2,2-difluoro-D-erythro-pentafuranous-1-ulose-3,5-dibenzoate
• Gemcitabine
• Methanesulfonic acid
• α-D-erythro-Pentofuranose-2-deoxy-2,2-difluoro-3,5-dibenzoate
• 2-DEOXY-2-FLUORO-D-ARABINOFURANOSE
• 2-DEOXY-2,2-DIFLUORO-D-RIBOFURANOSE-3,5-DIBENZOATE-1-METHANESULFONATE
• 2-Deoxy-2,2-difluoro-D-erythro-pentofuranose-3,5-dibenzoate-1-methanesulfonate